Zhao, Chao

TIM-3, a promising target for cancer immunotherapy

He, Y., Cao, J., Zhao, C., Li, X., Zhou, C., & Hirsch, F. (2018) · OncoTargets and Therapy

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 235

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?

Qiao, M., Jiang, T., Liu, X., Mao, S., Zhou, F., Li, X., Zhao, C., Chen, X., Su, C., Ren, S., et al. (2021) · Journal of Thoracic Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 186

EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies

Jia, Y., Li, X., Jiang, T., Zhao, S., Zhao, C., Zhang, L., Liu, X., Shi, J., Qiao, M., Luo, J., et al. (2019) · International Journal of Cancer

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 164

Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer

Zhao, S., Gao, G., Li, W., Li, X., Zhao, C., Jiang, T., Jia, Y., He, Y., Li, A., Su, C., et al. (2019) · Lung Cancer

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 164

Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy

Shi, J., Department of Medical Oncology, S. P. H. &. T. C. I., Yang, H., Jiang, T., Li, X., Zhao, C., Zhang, L., Zhao, S., Liu, X., Jia, Y., et al. (2017) · Chinese Journal of Cancer Research

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 37